Status of group B streptococcal vaccine development
Clinical and Experimental Vaccine Research
;
: 76-81, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-739634
ABSTRACT
Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies to substantially decrease GBS infection. In 2014, World Health Organization convened the first meeting for consultation on GBS vaccine development, focusing on the GBS maternal immunization program, which was aimed at reducing infections in neonates and young infants worldwide. Here, we review the history of GBS infections, the current vaccine candidates, and the current status of immunogenicity assays used to evaluate the clinical efficacy of GBS vaccines.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Polisacáridos
/
Streptococcus
/
Streptococcus agalactiae
/
Organización Mundial de la Salud
/
Vacunas
/
Higiene
/
Salud Global
/
Resultado del Tratamiento
/
Vacunas Conjugadas
/
Programas de Inmunización
Tipo de estudio:
Estudio diagnóstico
/
Guía de Práctica Clínica
Límite:
Anciano
/
Humanos
/
Lactante
/
Recién Nacido
Idioma:
Inglés
Revista:
Clinical and Experimental Vaccine Research
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS